Peptide YY (3-36), a synthetic human PYY 3-36, is a compound being evaluated for the treatment of obesity. It reduces appetite and increases satiety in obese patients.
Investigated for use/treatment in metabolic disease and obesity.
For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Salt Lake City, Utah, United States
Clinical Research Centre, University Hospital, Basel, Switzerland
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.